CHEST
Volume 161, Issue 2, February 2022, Pages e71-e73
Journal home page for CHEST

Novel Report
An Acute Exacerbation of Idiopathic Pulmonary Fibrosis After BNT162b2 mRNA COVID-19 Vaccination: A Case Report

https://doi.org/10.1016/j.chest.2021.07.2160Get rights and content

Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease characterized by progressive scar tissue formation. An acute exacerbation of IPF (AE-IPF) is a clinically significant respiratory decompensation that accounts for a significant proportion of IPF-related morbidity and mortality. AE-IPF can be idiopathic or associated with pulmonary embolism, infection, aspiration, surgery, and drug toxicity. In this novel case report, we describe a potential association between AE-IPF and BNT162b2 mRNA COVID-19 vaccination that was successfully treated with a short course of glucocorticoids. While our aim is to raise awareness for this yet-to-be-described adverse event, immunization against vaccine-preventable disease remains widely recommended in vulnerable patients with chronic lung disease such as IPF.

Key Words

acute exacerbation
BNT162b2 mRNA COVID-19 vaccine
COVID-19
idiopathic pulmonary fibrosis
interstitial lung disease

Abbreviations

AE-IPF
acute exacerbation of IPF
DI=ILD
drug-induced ILD
ILD
interstitial lung disease
IPF
idiopathic pulmonary fibrosis
SAE
serious adverse event

Cited by (0)

FUNDING/SUPPORT: A. G. was supported by T32HL 007778. CR was supported by the Boehringer-Ingelheim IPF/ILD Discovery Award and K08HL151970-01. E. L. H. was supported by R01HL109233, R01HL125850, R01HL152677, and grants from the Gabriel and Alma Elias Research Fund and the Greenfield Foundation.

View Abstract